1. Scrip
  2. >>Focus On Asia
  3. >>India

India Opens Gates To mRNA COVID-19 Vaccines, Moderna First Out

 
• By Anju Ghangurde

Moderna’s mRNA COVID-19 vaccine has been cleared in India for restricted emergency use, with expectations building for a go-ahead for Pfizer/BioNTech’s jab too, though it will be important to see how the country deals with the contentious issue of indemnity to vaccine makers.

moderna
Moderna gets go-ahead for COVID-19 vaccine in India • Source: Alamy

India has green-lighted Moderna, Inc.’s messenger RNA (mRNA) COVID-19 vaccine mRNA-1273 for restricted use in an emergency situation, with indications that things are also moving rapidly to close out outstanding issues and open the doors to Pfizer Inc.-BioNTech SE's similar mRNA vaccine in the country.

Moderna’s vaccine efforts in India are to be shepherded by Cipla Limited, which confirmed that it is “supporting” the US firm with the regulatory

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.